Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said ...
Shares of Hims & Hers Health (HIMS) shares plunged in late trading Monday after the company reported falling margins as costs ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...
We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE: NVO) stands against the other ...
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...
Eli Lilly is making a bold move with its experimental weight-loss pill, orforglipron, by recording nearly $550 million in ...
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...
We recently published a list of Top 10 Stocks to Buy According to Sustainable Insight Capital Management. In this article, we ...
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results